louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01398319: Prevention of Alcohol Related Incidents in the US Air Force
Official title: Prevention of Alcohol Related Incidents in the US Air Force
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Alcohol Abuse
Keywords: prevention
alcohol abuse
Lead sponsor: University of Virginia
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
name: United States Air Force
First posted: 2011-07-20
Enrollment: 26231
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Alcohol misuse poses significant public health concerns in the U.S. military. A Brief Alcohol Intervention (BAI) have been shown to reduce alcohol related incidents among Airmen undergoing training. The current study sought to examine whether a booster BAI administered at the end of an Airmen's training reduced alcohol related incidents out to a one-year follow-up. Participants were 26,231 US Air Force Technical Trainees recruited between March 2016 and July 2018. Participants were cluster randomized by cohort to two conditions: BAI + BAI Booster or BAI + Bystander Intervention. The primary analysis was a comparison of the interventions' efficacies in preventing Article 15 alcohol related incidents at a one-year follow-up, conducted using a generalized estimating equations logistic regression model controlling for covariates.


Eligibility criteria: Participants were Airmen undergoing Technical Training at five military bases (Lackland Air Force Base, Keesler Air Force Base, Sheppard Air Force Base, Goodfellow Air Force Base and Fort Sam Houston) in Texas and Mississippi from March 2016 through July 2018. Eligibility criteria included being at least 18 years of age and understanding the consent process in English.

Primary outcomes:
measure: Article 15s
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lackland Air Force Base
country: United States
facility: 37th Training Group
state: Texas
Study officials:
affiliation: University of Virginia
name: Robert C. Klesges, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04600219: The Effect of Tyrosine Kinase Receptor Axl on Dialysis Prognosis in Chronic Hemodialysis Patients
Official title: The Effect of Tyrosine Kinase Receptor Axl on Dialysis Prognosis in Chronic Hemodialysis Patients: a Cohort Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hemodialysis Complication
Keywords: hemodialysis
Axl
prognosis
Lead sponsor: Shanghai 10th People's Hospital
Sponsor class: OTHER
First posted: 2020-10-23
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: End-stage renal disease patients undergoing hemodialysis treatment

Brief summary: The purpose of this study is to evaluate whether tyrosine kinase receptor Axl affects the dialysis prognosis in chronic hemodialysis patients

Detailed description: It is reported that hemodialysis (HD) patients often develop chronic systemic inflammatoion, and increased inflammatory activity is associated with vascular access failure, cardiovascular disease and death in HD patients. The interaction of Axl and its ligand Gas6 plays an important role in modulating immune response, inhabiting toll-like receptor (TLR) signaling and suppressing inflammatory cytokines production. Thus, we want to investigate the relationship between tyrosine kinase receptor Axl and the dialysis prognosis in HD patients in three-years follow-up.

Eligibility criteria: Inclusion Criteria:

* hemodialysis for more than 6 months

Exclusion Criteria:

* patients who received warfarin therapy;
* patients with chronic infectious disease or acute infection;
* patients with hemodialysis inadequacy;
* the age of patients is older than 65 years or younger than 18 years.
* patients who can not sign an informed consent or disagree to follow up

Primary outcomes:
measure: death
timeFrame: 3 years
measure: dialysis complication
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital
state: Shanghai
Study officials:
affiliation: Shanghai 10th People's Hospital
name: Ai Peng, MD,PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02595619: Renal Replacement Therapy Plus Extracorporeal Carbon Dioxide Removal
Official title: Combined Strategy of Renal Replacement Therapy Plus Extracorporeal Carbon Dioxide Removal in Patients With Acute Kidney Injury
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Kidney Injury
Keywords: AKI
Extracorporeal Carbon Dioxide Removal
Renal Replacement Therapy
Mechanical Ventilation
Lead sponsor: University of Turin, Italy
Sponsor class: OTHER
First posted: 2015-11-03
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aims to assess whether in patients with acute kidney injury (AKI) requiring mechanical ventilation, a strategy that combines renal replacement therapy (RRT) and extracorporeal carbon dioxide removal (ECCO2R) allows reduction of tidal volume and plateau pressure. Systemic Inflammatory Response and Safety Variables will also be analysed.


Eligibility criteria: Inclusion Criteria:

* Patients with acute kidney injury (AKI) requiring renal-replacement therapy and mechanical ventilation of duration ≥ 48 hours

Exclusion Criteria:

* little chance of survival at 24 h (according to clinical judgment), pregnancy, mechanical ventilation with expected duration lower than 48h, age under 18 and over 90

Primary outcomes:
measure: Achievement of tidal volume reduction to 4 mL/kg while maintaining pH and PaCO2 to ± 20% of baseline values
timeFrame: 72 hours
Secondary outcomes:
measure: Evaluation of inflammatory mediators release in plasma samples of patients
timeFrame: 72 hours
measure: Assessment of the changes in pH
timeFrame: 72 hours
measure: Assessment of the changes in PaCO2
timeFrame: 72 hours
measure: Assessment of the changes in PaO2
timeFrame: 72 hours
Other outcomes:
Locations:
city: Turin
country: Italy
facility: Azienda Ospedaliera Città della Salute e della Scienza di Torino
Study officials:
References:
Clinical trial NCT06346119: Evaluation of the Impact of Touch Relaxation in Sedated Intubated Patients Hospitalized in Intensive Care at Niort Hospital
Official title: Evaluation of the Impact of Touch Relaxation in Sedated Intubated Patients Hospitalized in Intensive Care at Niort Hospital
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Reaction Anxiety
Difficult or Failed Intubation
Keywords: chemical restraint
intensive care
intubation
Lead sponsor: Centre Hospitalier de Niort
Sponsor class: OTHER
First posted: 2024-04-03
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This study will be conducted in two parallel groups. At the inclusion, each patient will be assigned to one of two groups by randomization; one group will receive the "touch" and the second group will not receive it will be the control arm.
Primary purpose: OTHER

Brief summary: This is a randomized prospective study. This objective is the impact of "relaxing touch" on the use of chemical restraint for patients in intensive care from the lifting of sedation until extubation.


Eligibility criteria: Inclusion Criteria:

* Male or female over 18 years of age
* Intubated and sedated man or woman
* Extubation within 48 hours
* Intubation of more than 48 hours in total
* Patient in intensive care at Niort hospital
* The trusted person or referent accepting the patient's participation
* Patient affiliated to the social security system

Exclusion Criteria:

* Known pregnancy
* Patient who refused to participate in the study after the fact
* Patients under long-term antidepressant treatment (treatment longer than 3 months)
* Patients under guardianship or curatorship
* Patient deprived of liberty
* Skin lesions on the hands/feet/head (wounds, erythema, burns, bedsores, phlyctenes)
* Inclusion in another clinical study

Primary outcomes:
measure: chemical restraint
timeFrame: 1 year
Secondary outcomes:
measure: self-extubations
timeFrame: 1 year
measure: patient discomfort
timeFrame: T=0, T=30 nimutes, T=60 minutes, T= 90 minutes
measure: respiratory rate
timeFrame: T=0, T=30 nimutes, T=60 minutes, T= 90 minutes
measure: Ratio chemical restraint use
timeFrame: 1 year
measure: cardiac frequency
timeFrame: T=0, T=30 nimutes, T=60 minutes, T= 90 minutes
Other outcomes:
Locations:
city: Niort
country: France
facility: Centre Hospitalier de Niort
Study officials:
affiliation: Centre Hospitalier de Niort - France
name: Jean Marc M. Le Guevel, Nurse coordinator
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06135519: Dermogenesis With Mesenchymal Stem Cells
Official title: Dermogenesis With Mesenchymal Stem Cells: A Fabulous Remedy For Post Acne Depressed Spots
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dermal Regeneration
Lead sponsor: King Edward Medical University
Sponsor class: OTHER
First posted: 2023-11-18
Enrollment: 20
Sex: ALL
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Group A with MSCs Group B with Fat
Primary purpose: TREATMENT

Brief summary: Dermogenesis With Mesenchymal Stem Cells in treating Post Acne Depressed Spots

Detailed description: management at two different stages of the course of the disease. First one at the stage of active disease which needs cleansers, antibiotics, retinoids, anti inflammatory agents and hormonal manipulation. Once active disease is over, patients report to clinician with depressed spots which are caused by localized dermal disruption and fat atrophy post inflammation or spontaneous epithelial rupture or scratching by the patient. These acne spots are hard to treat due to many reasons. Firstly, excision is difficult as size of most of them is small and they are in a large in number. Secondly, filling with and without subcision is not adequately addressing the deformity. Currently, a combination of filling with synthetic filler or fat and resurfacing by peeling, LASER or dermabrasion is in practice. In-spite of all, a treatment is still required to address post acne spots (Ice Spec Spots) adequately.

Eligibility criteria: Inclusion Criteria:

* Acne spots

Exclusion Criteria:

* Active acne

Primary outcomes:
measure: Dermal thickness
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: King Edward Medical University
state: Punjab
Study officials:
References:
Clinical trial NCT02624141: A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy
Official title: Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels, of Patients With Anemia Reklated to Malignant Tumors, Treated With Erythropoietin B (Recormon) Using the Pre-Filled Syringe With 30,000 IU, as Well as to Quantify Teh Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Anemia
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2015-12-08
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will examine the efficacy, safety, and effect on hemoglobin levels, of once weekly epoetin beta subcutaneous injections (30,000 International Units \[IU\]) in anemic patients with solid tumors. The anticipated study duration is 4 months, and the target sample size is 40 individuals.


Eligibility criteria: Inclusion Criteria:

* Adult patients with a non-myeloid malignancy
* Anemia

Exclusion Criteria:

* Transfusion of red blood cells within 2 months of study drug
* Treatment-resistant hypertension
* Acute or chronic bleeding (requiring therapy) within 3 months of study drug

Primary outcomes:
measure: Hemoglobin Levels at 16 Weeks
timeFrame: 16 Weeks
Secondary outcomes:
measure: Serum Iron Levels
timeFrame: 16 Weeks
measure: Quality of Life According to Functional Assessment of Cancer Therapy - Anemia (FACT-An) Instrument
timeFrame: Up to 4 months
measure: Tolerability - Incidence of Adverse Events
timeFrame: Up to 4 months
measure: Serum Transferrin Levels
timeFrame: 16 Weeks
measure: Percentage of Participants With A Positive Response
timeFrame: 16 Weeks
measure: Time To Global Response
timeFrame: Up to 4 months
measure: Quality of Life In Relation to Anemia Grade
timeFrame: Up to 4 months
measure: Serum Ferritin Levels
timeFrame: 16 Weeks
Other outcomes:
Locations:
city: Caracas
country: Venezuela
city: Valencia
country: Venezuela
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_CHAIR
References:
Clinical trial NCT01103141: Femoral Micropuncture or Routine Introducer Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Complications
Keywords: Vascular Surgical Procedures
Angioplasty
Radiology, Interventional
Lead sponsor: Cook Group Incorporated
Sponsor class: INDUSTRY
First posted: 2010-04-14
Enrollment: 143
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: FEMORIS is a marketing study approved by institutional review boards to compare the rates of complications found when using either the Micropuncture® needle introducer or a standard gauge-18 needle to access the groin blood vessels.


Eligibility criteria: Inclusion Criteria:

* Undergoing left heart catheterization with anticipated or possible percutaneous coronary intervention

Exclusion Criteria:

* Left heart cardiac catheterization purely for diagnostic purposes where percutaneous coronary intervention is not anticipated
* Catheterization utilizes primary vascular access site other than the groin
* Catheterization is intended for right heart procedure alone or combined with left and right heart procedures
* Age less than 18 years
* Patient has planned intervention or access utilizing the same groin within 14 days

Primary outcomes:
measure: Major Peripheral Vascular Events
timeFrame: 7 - 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Fresno
country: United States
facility: University of California, San Francisco, Fresno, School of Medicine
state: California
city: Indianapolis
country: United States
facility: St. Vincent Hospital
state: Indiana
Study officials:
References:
Clinical trial NCT03346941: Side Effects After Direct-acting Antiviral Treatment
Official title: Side Effects After Direct-acting Antiviral Treatment in Patients With Chronic Hepatitis C. The EFINO-C Study.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Hepatitis c
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2017-11-20
Enrollment: 95
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with chronic hepatitis C treated with direct-acting antiviral treatment

Brief summary: The objective of this study was to assess the incidence of side effects after direct-acting antiviral therapy in patients with chronic hepatitis C virus infection.

Detailed description: Direct-acting antiviral (DAA)-based treatments are today very effective The objective of this study was to assess the incidence of side effects after DAA therapy in patients with chronic hepatitis C virus infection.

Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* Hepatitis C virus infection
* Treatment by direct-acting antiviral combination

Exclusion Criteria:

* HIV coinfection

Primary outcomes:
measure: Incidence of side effects
timeFrame: Within treatment duration, i.e. 8, 12 or 24 weeks after treatment initiation
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Croix-Rousse Hospital, Hospices Civils de Lyon
Study officials:
References:
Clinical trial NCT00047541: Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70
Official title: Phase III Safety and Efficacy Study to Evaluate Combination IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertensive Patients C-01-70.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Open-Angle Glaucoma
Ocular Hypertension
Keywords: open-angle
glaucoma
ocular
hypertension
POAG
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2002-10-18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.


Eligibility criteria: Adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension; visual acuity of 20/80 to 20/400 or better (Snellen equivalent) or logMAR visual acuity not worse than 0.6. Clinically relevant ophthalmic or systemic conditions may be excluded.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: Clinical Trial Sites
state: Texas
Study officials:
References:
Clinical trial NCT04969341: Improving Lung Cancer Screening Adherence by Overcoming Barriers for Vulnerable Populations
Official title: Improving Lung Cancer Screening Barriers for Vulnerable Populations
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Carcinoma
Lead sponsor: Thomas Jefferson University
Sponsor class: OTHER
Collaborators: name: Prevent Cancer Foundation
First posted: 2021-07-20
Enrollment: 947
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients referred to the Jefferson Lung Cancer Screening Program (LCSP) and eligible for lung cancer screening

Brief summary: This study investigates multi-level barriers to lung cancer screening uptake and adherence to lung cancer screening. Identifying cost- and convenience-related barriers to lung cancer screening may help researchers develop targeted strategies to facilitate screening adherence specifically among vulnerable populations.


Eligibility criteria: Inclusion Criteria:

* All patients referred to the Jefferson LCSP and eligible for lung cancer screening by our standard criteria (United States Preventive Services Task Force, Center for Medicaid and Medicare Services, and/or National Comprehensive Cancer Network group II guidelines) will be eligible for inclusion in the study
* Additionally, individuals must provide a signed and dated informed consent form to participate in the survey portion of this study

Exclusion Criteria:

* Non-English-speaking individuals
* Individuals who lack consent capacity

Primary outcomes:
measure: Associations between health insurance availability and financial burdens as factors in lung cancer screening adherence
timeFrame: Up to study completion; 15 months
measure: Individual-level cost-related factors associated with screening adherence
timeFrame: Up to study completion; 15 months
measure: Convenience-related factors that impact lung cancer screening adherence
timeFrame: Up to study completion; 15 months
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Thomas Jefferson University Hospital
state: Pennsylvania
Study officials:
References:
Clinical trial NCT04689841: Influence of Short-term Vojta Therapy on the Gait in Healthy Adult Subjects.
Official title: Influence of Short-term Vojta Therapy on the Gait in Healthy Adult Subjects.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Gait, Frontal
Keywords: gait
Reflex Locomotion
Core stability
Ontogenesis
Neurorehabilitation
Neurological Disorder
Lead sponsor: NUMEN Foundation
Sponsor class: OTHER
Collaborators: name: Universidad Europea de Madrid
First posted: 2020-12-30
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The patterns of reflex locomotion described by Vojta contain all the basic patterns necessary for gait, which can be observed as partial patterns during normal postural ontogenesis in the first year of life. These patterns are triggered throughout life regardless of age, so they can be activated both in healthy subjects and in the presence of neurological pathology in adult patients.

Detailed description: In reflex locomotion, there is a coordinated and rhythmic activation of the entire skeletal muscles and different circuits of the central nervous system are stimulated. The motor reactions that are triggered regularly and cyclically due to pressure stimuli, from certain starting positions, are completely reproducible and as often as desired, even in the newborn child.

All the movements that appear in the development of the human being in grasping, turning, crawling, standing up and walking, are therefore visibly stimulated. They are, according to Prof. Vojta, present even in children of a developmental stage, in which they do not spontaneously yet possess these capacities.

Through the therapeutic application of reflex locomotion, those muscular functions used unconsciously and necessary for spontaneous daily motor skills are activated in the patient, especially in the spine, but also in the arms and legs, hands and feet and in the face.

Eligibility criteria: Inclusion Criteria:

* To be over 18 years old.

Exclusion Criteria:

* Present limitations or permanent or temporary injuries to the locomotor system.

Primary outcomes:
measure: 6 Minutes walk
timeFrame: one month
measure: EMG surface
timeFrame: two month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: